Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Operates as a Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Owns two 10,000 sq. ft. production facilities in Princeton, BC, with Drug Establishment Licence (DEL) and Dealer's Licence (DL) enabling legal manufacture and export.

• Products are available in Australia (for PTSD and TRD) and Canada (via Special Access Program); expansion plans target Israel and the U.S.

• Vertically integrated operations allow for rapid scaling, quality control, and pricing advantages.

• Winding down nutraceutical business to focus on pharmaceutical-grade manufacturing.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301, net loss C$3,712,031, accumulated deficit C$27,241,680.

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975.

• Cash and cash equivalents as of December 31, 2025: C$491,750.

• Ongoing operating losses, negative cash flow from operations, and reliance on equity and debt financing.

• Debt forgiveness of C$1,417,615 in FY2025 by directors.

Use of proceeds and capital allocation

• Net proceeds intended for scaling production and distribution in current markets, preparing for market entry to Israel and the U.S., sales growth, and general working capital.

• Management has broad discretion over use of funds; additional capital may be needed for U.S. market entry beyond 12 months.